Clinical Trial Update: Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma [Phase 2]

View source ↗

Summary

Phase 2 study of the investigational compound JNJ-39758979 for symptomatic adults with uncontrolled asthma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• JNJ-39758979

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Asthma | Phase 2 | Status: WITHDRAWN